Today's episode covers the latest advancements in mental health treatment by MIRA Pharmaceuticals (NASDAQ: MIRA), with promising preclinical trial results for compounds MIRA-55 and Ketamir-2. MIRA-55 offers therapeutic benefits without side effects like increased appetite or paranoia, while Ketamir-2 targets treatment-resistant depression. With a focus on patient care, MIRA aims to improve access and affordability, potentially changing the standard of care for neurological and neuropsychiatric disorders. In other news, Doubleview Gold Corp has resumed drilling at the Hat Project in Northern British Columbia, utilizing technical and statistical models to improve grade and explore mineralization trends for a future Mineral Resource Estimate.
